Katsuaki Maehara: Interesting indirect comparison analysis for Melanoma

Katsuaki Maehara shared a post on X:

“Melanoma Journal of Clinical Oncology.

• NCCN Guidelines recommended both Nivo+ Rela and Nico + Ipi as preferred, category 1, first-line systemic therapy options for unresectable or metastatic melanoma.
  
• An interesting INDIRECT comparison analysis has been published.”

• No difference in efficacy has been observed, but there are indications that Nivo + Rela tends to be better in terms of safety.

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Authors: Georgina V. Long, Evan J. Lipson, F. Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk3, Viviana Garcia-Horton, Zheng-Yi Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Divya Patel, Leon A. Sakkal, Hussein Tawbi, and Dirk Schadendorf.

Source: Katsuaki Maehara/X